Financing PrEP in the Current Era
Year Developed: 2023
Resource Type: Archived Webinar.Primary Audience: Clinicians
PCAs
Secondary Audience: Board of Directors
C-Suite (CEOs, CFOs, CIO, COOs, CMOs, etc.)
Enabling Staff
Outreach Staff
Language(s): English
Developed by: National LGBTQIA+ Health Education Center at The Fenway Institute (See other resources developed by this organization).
Resource Summary: In this webinar, Dr. Kevin Ard discussed recent developments in the field of PrEP, such as licensure of long-acting injectable medication for HIV pre-exposure prophylaxis (PrEP), availability of a generic PrEP formulation, and concerns about the 340B program. These developments have led to questions about financing PrEP in 2023 and beyond. In this interactive session, experts on PrEP will discuss the current PrEP financing landscape and what may be in store for the future.
Resource Topic: Clinical Issues, Emerging Issues, Special and Vulnerable Populations
Resource Subtopic: HIV/AIDS.
Keywords: Access to Care, LGBTQIA+, Physical Activity, Sexually Transmitted Infections (STIs).This project is supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) as part of an award totaling $6,625,000 with 0 percentage financed with non-governmental sources. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement, by HRSA, HHS, or the U.S. Government. For more information, please visit HRSA.gov.